0204 Merck Frazier
BioCentury & Getty Images

Product Development

Big shoes: Davis needs to fill Merck’s post-Keytruda pipeline as Frazier shifts to executive chair

Focus will be on modest, early-stage deals as the pharma seeks next blockbuster

As Ken Frazier’s successor as CEO, Robert Davis will need to deliver a pipeline robust enough to carry the pharma over Keytruda’s coming patent cliff. 

Feb 5, 2021 | 2:30 AM GMT

As Merck’s Robert Davis prepares to take the helm as CEO, his primary challenge will be executing on a pipeline robust enough to carry the

Read the full 891 word article

How to gain access

Continue reading with a
two-week free trial.